Combination Approaches Involving PD-1/PD-L1 Inhibition for Achieving Functional Cure in Chronic Hepatitis B
Background
Chronic hepatitis B (CHB) affects approximately 260 million people globally and is a leading cause of cirrhosis and hepatocellular carcinoma. Current therapies, including nucleos(t)ide analogues and pegylated interferon, often require long-term treatment to maintain viral suppression. Achieving a functional cure, defined as sustained HBsAg loss and durable viral control, remains a significant challenge due to immune dysfunction and viral persistence.
Data Highlights
No numerical data available in the source material.
Key Findings
PD-1/PD-L1 blockade can reinvigorate antiviral T-cell responses in CHB patients.
Early trials show significant reductions in HBsAg levels with PD-1/PD-L1 inhibitors.
A functional cure rate of 30% has been observed when combining PD-1/PD-L1 inhibitors with pegylated interferon, according to early clinical trials.
Challenges include optimizing dosing regimens and managing immune-related adverse events.
Future large-scale randomized controlled trials are necessary to assess the efficacy and safety of this approach.
Clinical Implications
The findings suggest that PD-1/PD-L1 inhibitors may enhance the effectiveness of existing therapies for CHB. Clinicians should consider the potential benefits and risks of these combination therapies in selected patients.
Conclusion
Combination regimens involving PD-1/PD-L1 blockade represent a promising strategy for achieving a functional cure in chronic hepatitis B, though further research is needed to refine their clinical application.
